Abstract
Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Although several hyperglycemia- elicited metabolic and hemodynamic derangements have been implicated in the pathogenesis of diabetic vascular complication, the process of formation and accumulation of advanced glycation end products (AGEs) and their mode of action are most compatible with the theory ‘hyperglycemic memory’. Further, there is a growing body of evidence that AGEs and their receptor (RAGE) axis is involved in the pathogenesis of diabetic vascular complication. Indeed, the engagement of RAGE with AGEs is shown to elicit oxidative stress generation and subsequently evoke inflammatory responses in various types of cells, thus playing an important role in the development and progression of diabetic micro- and macroangiopathy. These observations suggest that down-regulation of RAGE expression or blockade of the RAGE downstream signaling may be a promising target for therapeutic intervention in diabetic vascular complication. In this review, we discuss several types of agents that could potentially inhibit RAGE expression or its downstream pathways and their therapeutic implications in diabetic vascular complication.
Keywords: Diabetic vascular complication, AGEs, oxidative stress, RAGE
Current Pharmaceutical Design
Title: Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication
Volume: 14 Issue: 5
Author(s): Sho-ichi Yamagishi, Kazuo Nakamura, Takanori Matsui, Yoshihiro Noda and Tsutomu Imaizumi
Affiliation:
Keywords: Diabetic vascular complication, AGEs, oxidative stress, RAGE
Abstract: Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Although several hyperglycemia- elicited metabolic and hemodynamic derangements have been implicated in the pathogenesis of diabetic vascular complication, the process of formation and accumulation of advanced glycation end products (AGEs) and their mode of action are most compatible with the theory ‘hyperglycemic memory’. Further, there is a growing body of evidence that AGEs and their receptor (RAGE) axis is involved in the pathogenesis of diabetic vascular complication. Indeed, the engagement of RAGE with AGEs is shown to elicit oxidative stress generation and subsequently evoke inflammatory responses in various types of cells, thus playing an important role in the development and progression of diabetic micro- and macroangiopathy. These observations suggest that down-regulation of RAGE expression or blockade of the RAGE downstream signaling may be a promising target for therapeutic intervention in diabetic vascular complication. In this review, we discuss several types of agents that could potentially inhibit RAGE expression or its downstream pathways and their therapeutic implications in diabetic vascular complication.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Nakamura Kazuo, Matsui Takanori, Noda Yoshihiro and Imaizumi Tsutomu, Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication, Current Pharmaceutical Design 2008; 14 (5) . https://dx.doi.org/10.2174/138161208783597416
DOI https://dx.doi.org/10.2174/138161208783597416 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced Glycation End Products: A Link Between Periodontitis and Diabetes Mellitus?
Current Diabetes Reviews Contrast Medium Induced Nephropathy: New Insights into Prevention and Risk Management
Cardiovascular & Hematological Agents in Medicinal Chemistry Uncovering the Key miRNAs and Targets of the Liuwei Dihuang Pill in Diabetic Nephropathy-Related Osteoporosis based on Weighted Gene Co-Expression Network and Network Pharmacology Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease
Current Pharmaceutical Design Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Combination of Daidzein, Hemin and Bms182874 Halts the Progression of Diabetes-Induced Experimental Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets PPARγ Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?
Current Hypertension Reviews Systemic Involvement of IgG4-related Sclerosing Disease
Current Immunology Reviews (Discontinued) Recent Patents on Accuracy of Blood Pressure Measurement
Recent Patents on Biomedical Engineering (Discontinued) Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Modifiable Risk Factors for Premature Atherosclerosis in Systemic Lupus Erythematosus
Vascular Disease Prevention (Discontinued) Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety Inhibitors of the TGF-β Superfamily and their Clinical Applications
Mini-Reviews in Medicinal Chemistry Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Regulation of TGF-β Signaling by SMADs and its Roles in Tissue Fibrosis
Current Signal Transduction Therapy Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Use of High-Throughput Trypsin Digestion in Proteomic Studies
Current Proteomics Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine